TP53 and cancer: A next-generation sequencing (NGS) study on tumor tissues from 314 Chinese NSCLC patients delineated the mutational landscape in NSCLC, identifying TP53-p.Glu358Val as a driver mutation that activates mitophagy to support cancer cell growth (Wang et al., 2022).